Medicare

The administration said it would make the results of its drug price negotiations with manufacturers, as well as its approach to value-based care models, open to a variety of payers.

On January 1, CMS implemented the Hospital Price Transparency final rule, but by July, it was clear that many hospitals were noncompliant. Even with a proposed rule for penalties, requirements still only fall on certain parts of the health care industry.

Polypharmacy may be raising the risk of inappropriate medication use, and avoiding this is crucial.

The use of potentially inappropriate medications (PIMs) by older adults appeared to be linked to a greater risk of frailty, although the researchers said further work is needed.

Researchers offer recommendations for addressing polypharmacy and potentially inappropriate medication (PIM) use among older patients with cancer.

DOI: 10.37765/ajmc.2021.88735

The pandemic has shown a spotlight on how critically important respiratory care is to Americans who struggle to breathe on their own. Yet, Medicare policy must be updated to ensure that access to lifesaving equipment will never be disrupted.

Updated evidence provides new insight into safety, efficacy, and challenges of deprescribing.

Use of a smartphone-based application was found to improve medication adherence and some clinical outcomes in patients managing multiple comorbidities using polypharmacy, researchers concluded.

Late July brings a 64% enrollment increase; owner charged with fraudulently billing Medicare over $784 million; COVID-19 hot spots lose nurses due to burnout.

Identifying patients with combined polypharmacy and frailty can help recognize ICU patients with high risk of hospital readmission, the authors said.

Seventy percent of Americans have received at least 1 dose of a COVID-19 vaccine; CMS releases payment rules for fiscal year 2022; alcohol linked to over 700,000 new cancer diagnoses in 2020.

The study was conducted to shed more light on the growing issue of polypharmacy, an issue that is expected to increase as the US population ages.

Drug optimization in older adults improved outcomes in this retrospective study.

However, letting nurses have total control of medication management during hospital stays can create problems afterward.

While polypharmacy, along with hospital length of stay and other factors, was linked to a higher risk of 30-day hospital readmission, the type of medication mattered as well.

Future Medicare Part D models should consider alternative strategies to improve cost-related non-adherence.

Larger primary care practices in downside risk–only payment models and capitation saw the highest telemedicine utilization rates by their patients enrolled in Medicare Advantage (MA) plans.

High-tier generic drug placement in Medicare Part D has increased over time, but it may be related to a drug’s clinical profile and availability of substitutes rather than preferred brand-name drug coverage.

A string of controversies surrounding the approval of Biogen's Alzheimer disease drug aducanumab (Aduhelm) has not only called into question the independent nature of the FDA, but puts both providers and patients in a challenging position when it comes to deciding whether or not to prescribe or take the treatment.

On this episode of Managed Care Cast, Charlie Wray, DO, MS, an assistant professor of medicine at the University of California San Francisco, outlines the findings of a paper he coauthored which assessed Americans' experiences with their insurance providers.

Medicare Advantage plans may deliver care more efficiently to food-insecure beneficiaries than traditional Medicare, but they are not better at reducing food insecurity.

PBMs keep copays higher on the same generic drugs.

The Medicare Access and CHIP Reauthorization Act (MACRA) needs to be reimagined get back on track and to live up to its promise to incentivize value-based care.